AngioDynamics, Inc.

AngioDynamics, Inc.

ANGOยทNASDAQ

$10.98

+2.0%
HealthcareMedical - Instruments & Supplies

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

At a Glance

Live Snapshot
Market Cap$453.68M
EPS-0.8300
P/E Ratio-12.30
Earnings Date07/21/2026

Intrinsic Alpha Methodology

Thesis Lenses

Signal ยท Driver ยท Risk

Signal

Medium confidence

Valuation multiple is compressed (P/E -12.3).

Valuation inputs: P/E -12.3, earnings yield N/A, momentum +2.0%.

If multiples stay elevated while momentum fades, downside repricing risk rises.

Driver

High confidence

Return profile is soft (ROE -18.6%, ROIC -19.6%).

Profitability stack: net margin -11.6%, ROE -18.6%, ROIC -19.6%.

Quality deterioration often appears in margins before it shows up in headline EPS.

Risk

High confidence

Risk profile is balanced but has notable pressure points to monitor.

Risk factors: liabilities/assets +34.7%, momentum +2.0%, net margin -11.6%.

Higher leverage with weak momentum and thin margins can amplify drawdown severity.

ango

AngioDynamics, Inc. Market vs Earnings Trajectory

ANGO ยท NASDAQ

Loading price and EPS data...

AngioDynamics, Inc.

AngioDynamics, Inc. Fair Value Envelope

ANGO ยท NASDAQ

Our analysis suggests that ANGO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.98, this represents a potential HIDDEN relative to our calculated worth for AngioDynamics, Inc..

Intrinsic Value
Current Price: $10.98
3Y+22.0%
5Y-81.0%
10Y-33.0%
3Y-8.0%
5Y+11.0%
10Y-17.0%
3Y+28.0%
5Y-80.0%
10Y-22.0%
3Y+41.0%
5Y-30.0%
10Y-122.0%
3Y+27.0%
5Y-34.0%
10Y-137.0%
3Y-49.0%
5Y-53.0%
10Y-62.0%
AngioDynamics, Inc.

AngioDynamics, Inc. Profit Bridge

ANGO ยท NASDAQ
Revenue292.50M
Cost of Goods Sold (134.79M)
Gross Profit157.71M
Operating Expenses (197.66M)
Operating Income-39.95M
Interest Expense (0.00)
Other Income/Expense5.92M
Pretax Income-34.03M
Income Tax (-39.00K)
Net Income-33.99M
Net Income
-33.99M

Profitability Analysis

Gross Margin

53.9%

Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.

Operating Margin

-13.7%

Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.

Net Profit Margin

-11.6%

Net losses indicate the company is burning cash. Sustainability depends on path to profitability.

Profitability Insight

Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.

53.92%
Gross Profit Margin
6%
3Y+3.0%
5Y-5.0%
10Y+9.0%
-13.66%
Operating Profit Margin
-78%
3Y+52.0%
5Y-78.0%
10Y-4846.0%
-11.62%
Net Profit Margin
-81%
3Y+38.0%
5Y-82.0%
10Y-6.0%
-18.58%
Return on Equity
-79%
3Y+197.0%
5Y-49.0%
10Y+116.0%
-12.13%
Return on Assets
-79%
3Y+153.0%
5Y-57.0%
10Y+103.0%
-19.57%
Return on Invested Capital
-76%
3Y+278.0%
5Y-36.0%
10Y-1090.0%
ANGO

AngioDynamics, Inc. Cash Conversion Engine

ANGO ยท NASDAQ
Net Income-33.99M
Depreciation & Amortization25.80M
Stock-Based Compensation9.77M
Change in Working Capital-14.11M
Others3.39M
Capital Expenditures-4.46M
Free Cash Flow-14.59M

Cash Flow Quality Analysis

FCF Conversion Rate

42.9%

Weak cash conversion. Significant portion of earnings not converting to cashโ€”review working capital trends and capital intensity.

CapEx Intensity

-44.1%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+57.0%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

-$14.11M

Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extensionโ€”monitor closely.

Cash Flow Quality Insight

Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.

ango

AngioDynamics, Inc. Funding & Solvency Profile

ANGO ยท NASDAQ
Cash & Cash Equivalents37.81M
Net Receivables45.55M
Inventory58.58M
Other Current Assets13.61M
Total Current Assets156 M
Property, Plant & Equipment29.14M
Goodwill & Intangible Assets65.49M
Long-Term Investments0.00
Other Non-Current Assets10.50M
Total Non-Current Assets40 M
Total Assets
260.68M

Financial Health Analysis

Current Ratio

2.35x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.50x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

89 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

60% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

ango

AngioDynamics, Inc. Street Expectations Map

ANGO ยท NASDAQ

Wall Street analysts project that ANGO stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 16.50, with estimates ranging from a low of 12.00 to a high of 22.00.

Lowest Target
12.00
9.29%
Consensus Target
16.50
50.27%
Highest Target
22.00
100.36%

The consensus 1-year price target stands at 16.50, with estimates ranging from a low of 12.00 to a high of 22.00.

Analyst Consensus Analysis

Upside Potential

+50.3%

Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.

Analyst Agreement

60.6% spread

High uncertainty. Very wide target spread indicates significant disagreement among analystsโ€”major valuation uncertainty or transformation underway.

Analyst Conviction

Low

High uncertainty: Wide dispersion indicates analysts struggle to agree on valuationโ€”proceed with caution and independent analysis.

Market Sentiment Insight

High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.

ango

AngioDynamics, Inc. Insider Positioning

ANGO ยท NASDAQ

During the last 12 months, insiders have purchased $240K and sold $71K worth of ANGO shares, resulting in $168K of net buying activity.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

20.9K

239.53K

Sold

0

0.00

Net Activity

+240K

+$240K

9-12 Months

Bought

0

0.00

Sold

8.2K

71.32K

Net Activity

-71K

-$71K

Top Buyers

1
WLT

Weiss Lawrence T

Officer: Svp, Chief Legal Officer

10.0K sharesโ€ข1 transactions

$118K

2
CJC

Clemmer James C

Director, Officer: President And Ceo

10.0K sharesโ€ข1 transactions

$112K

3
TSA

Trowbridge Stephen A

Officer: Evp And Cfo

890 sharesโ€ข1 transactions

$10K

Top Sellers

1
TSA

Trowbridge Stephen A

Officer: Evp And Cfo

4.0K sharesโ€ข3 transactions

$35K

2
PL

Piccinini Laura

Officer: Svp International

2.6K sharesโ€ข2 transactions

$23K

3
NWJ

Nighan Warren Jr

Officer: Svp Quality And Regulatory

1.3K sharesโ€ข3 transactions

$11K

4
CJC

Clemmer James C

Director, Officer: President And Ceo

344 sharesโ€ข1 transactions

$3K

Insider Activity Analysis

Net Insider Sentiment

Bullish

Strong bullish signal with $168K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.

Buy/Sell Ratio

3.36:1

Exceptional buy/sell ratio. Buying dramatically outweighs sellingโ€”one of the strongest possible insider signals.

Insider Participation

Moderate Selling

4 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.

Insider Activity Insight

Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.

No Dividend Yield Data

ANGO has not reported any dividend yield values in the available annual periods.

ย 

ango Dividend History

ANGO
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%